US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

28.65

0.0000

Volume:- -

Turnover:6K

Market Cap:2.58M

PE:- -

High:28.65

Open:28.65

Low:28.65

Close:28.65

52wk High:29.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:0.92

Dividend Rate:3.20%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GH Research to Present TRD and Bipolar Trial Data at ECNP 2026

Teva announces FDA approval for Weltruza

Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

Xortx Therapeutics outlines anticipated clinical trial application for XRx-026

Arecor to Present Half-Year Results as It Advances Next-Generation Diabetes Therapies

Editas Medicine receives approval to initiate clinical trial of EDIT-401

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Biotech IPOs Charge Ahead as Tech Deals Stall

Samsung Projects Profit Surge of Eightfold to $80 Billion on AI Chip Demand

HanchorBio's Subsidiary Seeks Taiwan Nod for Solid Tumor Treatment

MT Newswires Live

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

3 Australian Biotech Stocks With At Least 64% Fair Value Upside

Simply Wall St.

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

Veru initiated with a Buy at WestPark Capital

Jupiter Neurosciences announces exploration of strategic options

Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NVIB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":28.651,"timestamp":1791552984406,"preClose":28.651,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"10-09 09:36:24 EDT","open":28.651,"high":28.651,"low":28.651,"amount":5862,"amplitude":0,"askPrice":28.79,"askSize":100,"bidPrice":28.72,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.651,"nav":29.611,"aum":2664977.22,"dividendRate":0.032048,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.6504,"preClose":28.651,"latestTime":"16:10 EDT","volume":6,"amount":171.906,"timestamp":1791490204365,"change":0.9994,"changeRate":0.034882,"amplitude":0},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"shares":90001,"dividePrice":0.9182,"high":28.651,"amplitude":0,"preClose":28.651,"low":28.651,"week52Low":24.54,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":28.651,"eps":0,"divideRate":0.032048,"volume":0,"delay":0,"ttmEps":0,"open":28.651,"prevYearClose":25,"prevWeekClose":29.1392,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":29.1392,"twentyDayClose":27.3696},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674785960","title":"GH Research to Present TRD and Bipolar Trial Data at ECNP 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785960?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:27","pubTimestamp":1791545234,"startTime":"0","endTime":"0","summary":"GH Research ( ($GHRS) ) has issued an announcement. GH Research PLC announced that data from its GH001-TRD-201 and GH001-BD-202 clinical trials wil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-trd-and-bipolar-trial-data-at-ecnp-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-trd-and-bipolar-trial-data-at-ecnp-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","GDOC","IDNA","HYLG","BMED","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674785642","title":"Teva announces FDA approval for Weltruza","url":"https://stock-news.laohu8.com/highlight/detail?id=2674785642","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674785642?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543924,"startTime":"0","endTime":"0","summary":"Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-for-weltruza-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","LFSC","TEVA","MRNY","GDOC","BK4588","BK4566","BK4007","IYH","XLVX","BBP","BK4596","IDNA","MEDI","TECB","BMED","LABU","NVIB","BK4557","IBB","LU2324357040.USD","FRTY","BK4584","IEIH","SYNB","GNMX","TBXU","RSPH","LU1983299246.USD","PINK","BK4559","BK4585","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674985629","title":"Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2674985629","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674985629?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:05","pubTimestamp":1791543914,"startTime":"0","endTime":"0","summary":"Glaukos (GKOS) announced topline results from the Phase 4 prospective, randomized, controlled clinical trial evaluating iDose TR administered in co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/glaukos-announces-phase-4-trial-of-idose-tr-met-primary-efficacy-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/glaukos-announces-phase-4-trial-of-idose-tr-met-primary-efficacy-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","HYLG","IE0009354923.USD","LU2065731478.USD","LU1878469433.USD","GDOC","BK4082","NVIB","GKOS","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856429","title":"Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856429?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543600,"startTime":"0","endTime":"0","summary":"Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflamma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/09/3377993/0/en/sagimet-to-present-positive-full-52-week-results-from-license-partner-ascletis-phase-3-open-label-extension-clinical-trial-of-denifanstat-in-acne-and-mechanistic-data-at-the-2026-f.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","IDNA","MEDX","IGA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674856405","title":"X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders","url":"https://stock-news.laohu8.com/highlight/detail?id=2674856405","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674856405?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:00","pubTimestamp":1791543600,"startTime":"0","endTime":"0","summary":"BOSTON, Oct.  09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will ho","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/09/3377996/0/en/x4-pharmaceuticals-to-host-virtual-investor-day-on-thursday-october-29-2026-featuring-key-opinion-leaders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","MEDX","IDNA","BK4109","KEM","GDOC","HYLG","ASH","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000503","title":"Xortx Therapeutics outlines anticipated clinical trial application for XRx-026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000503?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489913,"startTime":"0","endTime":"0","summary":"Xortx Therapeutics (XRTX) provided an outline of its anticipated clinical trial application, or CTA, submission to Health Canada for the XRx-026 go...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-outlines-anticipated-clinical-trial-application-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-outlines-anticipated-clinical-trial-application-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","HYLG","IDNA","MEDX","GDOC","CTA","NVIB","JPFP","DBMF","SDMF","BK4139","ISMF","LENZ","XRTX","TFPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673072167","title":"Arecor to Present Half-Year Results as It Advances Next-Generation Diabetes Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2673072167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673072167?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:04","pubTimestamp":1791461092,"startTime":"0","endTime":"0","summary":"Arecor Therapeutics PLC ( ($GB:AREC) ) has provided an announcement. Arecor Therapeutics plc, a Cambridge-based clinical-stage biotech, is developi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arecor-to-present-half-year-results-as-it-advances-next-generation-diabetes-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arecor-to-present-half-year-results-as-it-advances-next-generation-diabetes-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071338","title":"Editas Medicine receives approval to initiate clinical trial of EDIT-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071338?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457602,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4556","IDNA","EDIT","BK4139","MEDX","HYLG","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673714960","title":"Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673714960","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673714960?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457200,"startTime":"0","endTime":"0","summary":"Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377124/0/en/editas-medicine-receives-approval-to-initiate-first-in-human-clinical-trial-of-edit-401-in-patients-with-hyperlipidemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","HYLG","SYNB","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673785620","title":"Biotech IPOs Charge Ahead as Tech Deals Stall","url":"https://stock-news.laohu8.com/highlight/detail?id=2673785620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673785620?lang=en_us&edition=fundamental","pubTime":"2026-10-08 17:30","pubTimestamp":1791451800,"startTime":"0","endTime":"0","summary":"Biotechnology companies are sprinting to the public markets and defying a broader IPO slowdown.Twenty-three biotechs staged initial public offerings in the first three quarters this year, nearly tripl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK4588","REDS","BK4581","XBIX","BK4585","NVIB","FRHC","IPO","XBI","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117753774","title":"Samsung Projects Profit Surge of Eightfold to $80 Billion on AI Chip Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1117753774","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117753774?lang=en_us&edition=fundamental","pubTime":"2026-10-08 14:30","pubTimestamp":1791441027,"startTime":"0","endTime":"0","summary":"Samsung Electronics has estimated that its third-quarter operating profit soared nearly ninefold, as robust demand for memory chips from AI companies continues to create a supply shortage across the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMXC","BK4588","INTW","MUU","MIC","LINT","MUZ","INYY","BK4585","MULL","PSAI","INT","AMAU","NVIB","MUG","AMA","MUYY","MUD","APMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673040775","title":"HanchorBio's Subsidiary Seeks Taiwan Nod for Solid Tumor Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673040775","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673040775?lang=en_us&edition=fundamental","pubTime":"2026-10-08 12:43","pubTimestamp":1791434637,"startTime":"0","endTime":"0","summary":"HanchorBio's  subsidiary, FBD Biologics, has submitted an Investigational New Drug application to the Taiwan Food and Drug Administration  for clinical trial review of HCB303, a trispecific fusion protein being developed for the potential treatment of solid tumors.The application follows the recent receipt of approval from the U.S. Food and Drug Administration for HCB303, according to a Wednesday filing to the Taiwan Stock Exchange.TFDA approval and applicable institutional ethics approval will pave the way for patient enrollment for the trial in Taiwan.Following receipt of the required regulatory and institutional ethics approvals, the company plans to conduct Phase I, Phase II, and Phase III clinical trials sequentially.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDNA","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEIH","LU0320765489.SGD","LFSC","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BBP","BK4578","SYNB","TECB","IE00BFTCPJ56.SGD","PINK","BMED","IBB","BK4585","XLVX","MEDX","PSCH","IE0002141913.USD","LU0070302665.USD","BK4588","IE00B4R5TH58.HKD","IDNA","IE0009355771.USD","NVS","MEDI","GDOC","BK4007","IYH","NVIB","LU0211331839.USD","GNMX","FRTY","MRNX","LABU","TBXU","IE00BJT1NW94.SGD","MRNY","BK4532","RSPH","PPH","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","RSPH","LU1244550221.USD","MEDI","BBP","BK4581","IE00B3S45H60.SGD","IAI","LU0267386448.USD","LU0795875169.SGD","SYNB","TBXU","LU1064131342.USD","IYH","LU0390134368.USD","BMED","IE00BZ1G4Q59.USD","KBWB","LU2023251221.USD","IDNA","GNMX","GDOC","LU2264538146.SGD","FRTY","LU2487616109.SGD","MRNY","PSCH","LABU","BK4504","LU0210528500.USD","LU1720051017.SGD","TECB","XLVX","LU0528227936.USD","BK4585","NVIB","LU0912757837.SGD","LU1720051108.HKD","MRNX","IBB","LU1668664300.SGD","LU2357305700.SGD","SD","LFSC","LU2028103732.USD","LU1791710582.SGD","LU1989772840.SGD","LU2089284900.SGD","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013770","title":"AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013770","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013770?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:14","pubTimestamp":1791378840,"startTime":"0","endTime":"0","summary":"CEO interview explores Ampligen’s potential to extend survival and improve quality of life as AIM advances toward pivotal development Access the article here OCALA, Fla., Oct.  07, 2026 (GLOBE NEWSWIR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376540/29489/en/aim-immunotech-s-strategy-to-address-immune-resistance-in-pancreatic-cancer-featured-in-biotuesdays.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","NVIB","HYLG","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011506","title":"3 Australian Biotech Stocks With At Least 64% Fair Value Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011506","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011506?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:48","pubTimestamp":1791373688,"startTime":"0","endTime":"0","summary":"IMF warnings about high public debt and the risks around rapid AI investment have pushed many investors to look for sectors where real science backs the story. Australian biotech stocks fit that brief, with businesses built around research pipelines rather than hype. For investors willing to handle higher risk, this corner of the market can be compelling. This article highlights three stocks from our biotech screen that may warrant closer examination.\nThe three biotech stocks below are only a...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-at-least-64-fair-value-upsi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-vls/vita-life-sciences-shares/news/3-australian-biotech-stocks-with-at-least-64-fair-value-upsi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XBI","VAP.AU","VLS.AU","ZYAU.AU","XKO.AU","IMLC.AU","XJO.AU","BEAR.AU","QRE.AU","BK4581","BK7508","SLF.AU","QFN.AU","BBOZ.AU","OZF.AU","EIGA.AU","BK4585","IIGF.AU","IOZ.AU","DACE.AU","CUV.AU","BK4588","XBIX","BK7067","AIPO","BK7096","IISV.AU","STW.AU","XAO.AU","GEAR.AU","NVIB","MYX.AU","OZR.AU","E200.AU","GIVE.AU","VAS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673975950","title":"Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673975950","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673975950?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:00","pubTimestamp":1791370800,"startTime":"0","endTime":"0","summary":"– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376329/0/en/arvinas-shares-novel-oculomotor-and-biomarker-data-from-phase-1-clinical-trial-of-arv-102-in-patients-with-parkinson-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4109","LU2463526074.USD","CSF","HYLG","PSP","ASH","GDOC","NVIB","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706884","title":"Veru initiated with a Buy at WestPark Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706884?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:40","pubTimestamp":1791308410,"startTime":"0","endTime":"0","summary":"WestPark Capital initiated coverage of Veru (VERU) with a Buy rating and $28 price target Lead asset enbosarm has completed 27 clinical trials acro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veru-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veru-initiated-with-a-buy-at-westpark-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","BK4557","DBB","GDOC","BMED","BK4007","IDNA","NVIB","VERU","MEDX","BK4183","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673575850","title":"Jupiter Neurosciences announces exploration of strategic options","url":"https://stock-news.laohu8.com/highlight/detail?id=2673575850","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673575850?lang=en_us&edition=fundamental","pubTime":"2026-10-06 23:25","pubTimestamp":1791300325,"startTime":"0","endTime":"0","summary":"Jupiter Neurosciences (JUNS) announced that the first patient has been dosed in the company’s Phase 2a RESET clinical trial evaluating JOTROL in pa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jupiter-neurosciences-announces-exploration-of-strategic-options-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jupiter-neurosciences-announces-exploration-of-strategic-options-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4007","JUNS","IDNA","NVIB","GDOC","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705514","title":"Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705514","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705514?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:35","pubTimestamp":1791286532,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-efficacy-data-from-phase-2-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","MEDX","HYLG","KAPA","BK4139","PSIL","KAIR","IDNA","NVIB","BBC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}